IQVIA Holdings Inc. (NYSE:IQV) Receives $237.62 Consensus Target Price from Analysts

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-four ratings firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $231.71.

A number of analysts recently commented on the company. HSBC cut IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Mizuho decreased their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, Truist Financial decreased their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares during the last quarter. Geode Capital Management LLC increased its holdings in IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after purchasing an additional 77,981 shares during the last quarter. Invesco Ltd. increased its holdings in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after purchasing an additional 59,426 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of IQV stock traded down $4.39 during mid-day trading on Tuesday, reaching $148.90. The stock had a trading volume of 1,677,229 shares, compared to its average volume of 1,469,448. IQVIA has a 12-month low of $135.97 and a 12-month high of $252.88. The company has a market cap of $25.76 billion, a P/E ratio of 19.85, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The business has a 50-day simple moving average of $163.91 and a 200 day simple moving average of $188.09. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.54 EPS. On average, sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.